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Classic studies by Rowe et al . (1) in the human and by Vitetta and coworkers (2)
in the mouse have established that IgD is a major membrane immunoglobulin . This
has led to a variety of studies and speculation regarding its biological function . Based
upon the effect of anti-IgD on the in vitro primary response, Cambier et al . (3)
suggested that the presence of IgD on the cell surface was critical for responses to
thymus-dependent but not thymus-independent antigens . Prolonged in vivo treatment
of mice with anti-IgD, starting at birth, was reported by Layton et al . (4) to result in
a decrease in the incidence ofIgD positive cells, accompanied by a depression in the
secondary indirect plaque-forming cell, (PFC) i response . In contrast, Bazin et al . (5)
found that treatment with antiserum to IgD from birth led to little or no decrease in
any of the immunoglobulin classes except for IgE, which was markedly reduced . IgE
antibody responses were also depressed .
As in the case ofthe other immunoglobulin classes, allelic exclusion has been shown
to exist for IgD (6, 7) . The availability of monoclonal allotype-specific antibody to
IgD allows the investigation of the effects of anti-IgD in allotype heterozygous mice,
with restriction ofthe effects limited to one halfof the B cell population . Comparison
with the alternative allelic products permits a sensitive study of the role of IgD in
immune responses with an ideal internal control . Furthermore, anti-IgD treatment of
heterozygous or ofhomozygous mice might provide a clue to phenomena of internal
balance and compensation (regulation) within an immune system . We therefore
decided to re-investigate several aspects of the effects of anti-IgD on the immune
system : (a) to compare the effect of anti-delta suppression in homozygous and
heterozygous animals ; (b) to determine whether IgD suppression is linked to the
suppression of the corresponding IgG allotypes ; and (c) to determine the effect of
functional inactivation of all delta-positive cells on the development of germinal
centers and on memory cell generation .
* Supported in part by grants AI-11694, AI-14398, AI-03076, and AI-14829 from the National Institutes
of Health, Bethesda, Md .
$ Supported by training grant 5T32 CA-09161 from the National Institutes of Health .
' Abbreviations used in this paper: BA, Brucella abortus ; BGG, bovine gammaglobulin ; CFA, complete
Freund's adjuvant ; KLH, keyhole limpet hemocyanin ; PBS, phosphate-buffered saline; PFC, plaque-
forming cells ; SRBC, sheep erythrocytes ; TBS, Tris-buffered saline; TNP, trinitrophenyl .
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Materials and Methods
Mice.
￿
BALB/c mice, homozygous for a allotypes, and SJL mice, homozygous for b allotypes,
were bred in the animal facility at New York University Medical School, New York. (BALB
X SJL)F, allotype heterozygotes were bred in the animal facility of the Department of
Immunology, Merck and Co ., Rahway, New Jersey . BALB/cAN mice used for breeding
homozygotes were obtained from Charles River Laboratories, Inc ., Wilmington, Mass . BALB/
CAN females used for breeding heterozygotes were obtained from Simonsen Laboratories,
Gilroy, Calif All SJL breeding mice were obtained from The Jackson Laboratory, Bar Harbor,
Maine .
Antigens.
￿
Sheep erythrocytes (SRBC) were purchased from Colorado Serum Co ., Denver,
Colo . ; keyhole limpet hemocyanin (KLH) was purchased from Schwarz/Mann Div ., Becton,
Dickinson & Co ., Orangeburg, N . Y . ; Ficoll, 40,000 mol wt, was obtained from Pharmacia Fine
Chemicals, Div. of Pharmacia, Inc ., Piscataway, N . J . ; and trinitrophenyl sulfonic acid was
purchased from Sigma Chemical Co ., St . Louis, Mo . Brucella abortus (BA) was provided by the
U . S . Department of Agriculture, Ames, Iowa . TNP-BA and TNP-KLH were prepared as
described by Little and Eisen (8) and TNP-Ficoll was prepared according to the method of
Mitchell et al . (9) .
Antibodies.
￿
Anti-IgD hybridoma 10-4.22, producing molecules of the IgG2a class directed
against specificity four of the Ig-5a allele (10) was obtained from Dr. Virgil Wood, National
Institutes of Health . The cells were grown in RPMI-1640 with 10% fetal calf serum, glutamine
(2mM), and sodium pyruvate (I mM) in the presence ofpenicillin, streptomycin, and fungizone
(100 U, 100 ltg, and 0.25 )tg/ml) . Cells were then allowed to secrete for 1 wk without feeding,
and the supernate was absorbed on a Staph A-Sepharose 4B column . The antibodies were
eluted with 0 .1 M sodium citrate, pH 3.0, dialyzed against phosphate-buffered saline (PBS),
and sterilized by filtration . Monoclonal antibodies of the IgM class directed against specificity
three ofallele Ig-56 from line H6-31 (11) were purchased from Accurate Chemical and Scientific
Corporation (Hicksville, N . Y .), distributors for Sera Labs (London, England) . A rabbit anti-
mouse IgD antiserum, the preparation of which is described elsewhere (12) was kindly donated
by Dr. F . Finkelman, National Institutes of Health . Anti-mouse IgM antiserum was prepared
by immunizing a goat with the IgM lambda myeloma MOPC104E . The antiserum was
absorbed with insolubilized IgA lambda myeloma protein J558 and with polyclonal mouse
IgG . Anti-mouse Ig F(ab')2 was prepared by immunizing a rabbit with normal mouse Ig in
complete Freund's adjuvant (CFA) . The antiserum was precipitated with 30% (NH4)2SO4 and
pepsin digested as described by Nisonoffet al . (13) . The digest was passed over a Sepharose 4B
column conjugated with a mixture of mouse IgG, IgA, and IgM, and eluted at acid pH .
Allotype-specific antisera were prepared by immunizing mice as previously described (14) .
Antibodies specific for IgG2a allotypes (anti-Ig-la and anti-Ig-lb) were prepared by passing the
relevant anti-allotype serum over Sepharose 4B columns to which purified myeloma proteins,
RPC5 (Ig-la) and CBPC101 (Ig-lb) were coupled . The specific antibodies were eluted with 3.5
M MgC1 2 , neutralized, dialyzed, and concentrated by vacuum dialysis .
Immunization.
￿
Homozygotes were injected intravenously at 3-4wk of age (day 0) with either
10 tag TNP-Ficoll, 100 Itg TNP-KLH, or 800 hg TNP-BA . Primary PFC responses to TNP-
Ficoll and TNP-KLH were determined 4 d after immunization . Mice injected with TNP-BA
were boosted 10 d later, and their splenic secondary PFC responses were determined 4 d after
the last injection . Serum titers, determined in a few mice, were tested on day 7 of the primary
or secondary response . In two experiments, TNP-BA was injected into the front footpads on
days 0 and 10, using 0.8 ftg for priming and either 0.8 or 8 ltg for the boost . Cells from the
draining lymph nodes were assayed for antibody producing cells 4 d after the boost . Hetero-
zygotes were primed at 6 wk of age and boosted at 11 wk of age with 4 X 10 8 SRBC,
administered intravenously . The antigen was given 1 d after an injection of anti-IgD . The mice
were used for assay 6 d after the second antigen injection (7 or 42 d after the last anti-IgD
injection) .
Schedule of Anti-IgD Injections.
￿
BALB/c and SJL/J homozygotes were injected with anti-5a
or anti-5b, respectively, three times weekly, using the following doses : 5 Ng per injection from
day 0 to day 10 ; l0 ltg per injection from day 10 to day 20, and 501ug per injection from day
21 until assay . Littermate controls were either not injected or were given the same amounts of320
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nonspecific myeloma protein (CBPC101 or LPCI). (BALB x SJL)Fi heterozygotes were
injected once a week with anti-5a and/or anti-5b. Four different injection schedules, designed
to coincide with different stages of the immunization period, were used as follows: (a) from
birth through week 11, covering the entire immunization period; (6) birth to week 6, the time
of primary immunization; (c) week 6 to week 11, from priming to boost; and (d) a single
injection on week 6, the time of priming only. Mice injected from birth (day 0) were given 10
,ug ofantibody on days 0, 7, 14, and 21 . Beyond this age, mice were injected, on the appropriate
weeks, with 2 ltg of antibody per gram body weight. Littermate controls were not injected.
Immunofluorescence.
￿
Membrane immunofluorescence was performed by staining the cells at
4°C in the presence of sodium azide as previously described (15) . Staining for Ig positive cells
was done using rhodamine-conjugated rabbit anti-Ig F(ab~2. The staining for IgD allotypes
was done in some experiments by reacting the cells with purified monoclonal anti-IgD followed
by fluorochrome-conjugated, pepsin-digested rabbit antibody against mouse IgG. This partic-
ular antiserum, absorbed with mouse F(ab~2, reacted only with determinants of the mouse
gamma chains not accessible on membrane-bound IgG endogenous to the lymphocytes. Thus,
staining with this antiserum in the absence of previously added anti-IgD antibodies gave no
background. Most of the staining was performed with purified anti-delta allotype monoclonal
antibodies conjugated with biotin hydroxysuccinimide, followed by fluorochrome-conjugated
avidin. For conjugation with biotin, proteins at concentrations of 0.1-1.0 mg/ml were dialyzed
against0.9%NaCl, and I MNaHCO3 was added to this solution to bringthe finalconcentration
to 0.1 M. Biotin hydroxysuccinimide, synthesized as described by Becker et al. (16), or
purchased from Pierce Chemical Co., Rockford, III., was dissolved in dimethyl sulfoxide at a
concentration of 10 mg/ml and added to the protein solution at a 1:5 ratio. The mixture was
left at room temperature for 90 min and then dialyzed against PBS. Fluorescein or rhodamine-
conjugated avidin was purchased from Vector Laboratories (Burlingame, Calif.) and was
routinely used at 100 g,g/ml. The stained cells were viewed with a Leitz Dialux microscope (E.
Leitz, Inc., Rockleigh, N. J.) equipped with a vertical illuminator and Ploem optics, allowing
selective visualization of rhodamine or fluorescein.
Histology andImmunoperoxidase Staining.
￿
For routine histology, tissues were fixed in Carnoy's
solution and stained with methyl green pyronin. For IgD staining, lymph nodes were fixed in
cold ethanol, infiltrated, and embedded in ethanol soluble polyester wax (Gallard-Schlesinger
Chemical Mfg. Corp., Carle Place, N. Y.), as described by Sordat et al. (17). Four micron
sections were placed on glass slides previously coated with amylopectin (Chemalog, Plainfield,
N. J.). The sections were incubated in 0.5% H202 in methanol for 30 min to eliminate
endogenous peroxidase activity and washed with 0.05 M Tris-bufferedsaline (TBS). Allsections
were incubated with normal goat serum (1 :10) for 10 min. The excess serum was wiped away
and the sections were overlayed with rabbit anti-mouse IgD, diluted to 5 Jug/ml, for 60 min.
Control sections were incubated with 1% normal rabbit serum in TBS. All sections were
subsequently incubated with goat anti-rabbit serum (N. L. Cappel Laboratories, Inc., Coch-
ranville, Pa.), diluted 1:100,and peroxidase rabbit anti-peroxidase (N. L. Cappel Laboratories),
diluted 1:1,500, each for 30 min. Between incubations, the sections were washed for 10 min in
threechangesofTBS. Thesections were stainedwith 3, 3' diaminobenzidine tetrahydrochloride
(Sigma Chemical Co.), 0.02% and hydrogen peroxide, 0.003% in TBS, pH 7.6, for 7 min. The
reaction was terminated by washing in TBS. The sections were counterstained with methyl
green.
PFC Assay.
￿
Anti-SRBC and anti-TNP PFC were assayed by the slide modification (18) of
theJerne technique (19) . TNP-SRBC were prepared usingthe method describedby Rittenberg
et al. (20). IgG-producing cells from homozygotes were developed with rabbit anti-mouse Ig
and, from heterozygotes, with allotype-specific alloantisera.
Quantitation of Serum IgG2a.
￿
Serum levels of IgG2a were determined by means of the solid-
phase radioimmune blocking assay described by Tsu and Herzenberg (21) . Purified myeloma
proteins RPC5 (Ig-la) and CBPC101 (Ig-lb) were used to coat the wells and, in graded
concentrations, to provide the standard curve against which the test samples were read. The
purified antibodies, anti-Ig-la andanti-Ig-lb, were radioiodinated by thechloramine Tmethod
(22).Serum Titers.
￿
Antibody titers were determined against TNP-sensitized SRBC (20) or BA,
using standard agglutination techniques (23) .
In Vivo Suppression ofIgD-bearing Cells and Their Recovery in Heterozygous and Homozygous
Mice. BALB/c mice, injected with anti-Ig-5a starting at birth, were examined at
various times for the incidence of splenic IgD- and Ig-bearing cells. As indicated in
Table I, this treatment resulted in a profound suppression of IgD-positive cells and a
reduction in the total number of Ig-bearing cells to ~30% of normal. Staining with
rabbit anti-delta also failed to reveal any IgD-bearing cells (data not shown). After
termination of treatment with anti-IgD, recovery of IgD-bearing cells was relatively
slow, being minimal at 5 d and only partial at 11 d. There was a roughly parallel
increase in total Ig-bearing cells.
Heterozygous (BALB X SJL)Fi mice, treated from birth with anti-IgD directed
against one allotype, exhibited a profound suppression of IgD-bearing cells of that
allotype when examined 7 d after the last injection of anti-IgD (Table II). 6 wk after
the last injection, the allotype distribution of the IgD-bearing cells was still abnormal
and recovery was only partial. The serum concentration of IgG28 of the linked
(suppressed) allotype was also markedly depressed 7 d after the last injection of anti-
IgD and was only approaching 50% of normal 6 wk later. Thus, the recovery of the
serum IgG2a concentration mirrored that of IgD-positive cells in the spleen.
Heterozygous mice injected simultaneously with anti-IgD antibodies directed
against each of the IgD allotype specificities showed a reduction in the incidence of
IgD-bearing cells of both allotypes at 7 d after the last injection . However, in contrast
to the situations with heterozygous mice treated with antibody to only one allotype,
the serum levels were only slightly reduced for both IgG2a allotypes. In fact, five of the
six animals studied had levels falling within the normal range and only one animal
had low levels (17 .8 and 36.3% of normal for the a and b allotypes, respectively).
TABLE I
Suppression and Recovery ofIgD-bearing Cells after Treatment of BALBIc
Mice with Anti-Deltafrom Birth
JACOBSON ET AL.
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Results
Incidence of sleen cells
* Determined by immunofluorescence. Expressed as arithmetic mean t SE.
Numbers of mice are in parentheses.
$ Intraperitonal injections of 4.22 anti-5a given three times a week: 5 jig in the
first 10 d, 10 gg in the next 10 d, and 50 lag thereafter.
Treatment
Day after last
anti-delta
injection
d
Age of
mice
d
IgD
bearing*
Ig
None - 33-35 20.4 t 2.7 22.1 ± 4.6 (8)
None - 38-42 34.6 ± 2.5 37.3 ± 1.3 (9)
Anti-delta$ 1-2 27-35 0.8 ± 0.5 7.5 t 0.6 (5)
Anti-delta 2 39-42 1 .2 t 0.6 8.3 t 0.8 (11)
Anti-delta 4 35 1.6 11 .9 (2)
Anti-delta 5 35-38 3.3 t 1.0 9.4 ± 1.6 (7)
Anti-delta 9 42 10.2 t 2.6 18.8 ± 1.7 (5)
Anti-delta 11 41 19.7 t 0.6 19.7 ± 1.8 (3)322
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TABLE 11
Suppression and Recovery of IgD-bearing Cells after Treatment of (BALBIc
X SJL)F, Mice with Anti-Delta from Birth
Treatment
* Days 0, 7, 14, and 21: 10 fig injected intraperitoneally. Thereafter, weekly
injections of 2 fig/g body weight were given. All mice were assayed at 84 d
of age.
$ Determined by immunofluorescence .
§ Determined by radioimmune blocking assay.
Histological Observations on the Effect ofAnti-IgD Treatment ofHomozygous Mice.
￿
Spleen,
lymph nodes, and Peyer's patches of suppressed and control BALB/c mice, 5-7 wk
old, were examined histologically. In agreement with observations of others (24),
germinal centers were present in apparently normal numbers in all tissues of sup-
pressed mice that were examined (Fig. 1). The morphology of the germinal centers
was also normal except for a distinct decrease in the numbers of small lymphocytes in
the mantle zones. Primary follicles (Fig. lA and B) also appeared less dense than in
control mice. Staining with rabbit anti-IgD revealed a complete absence of IgD-
bearing cells in the spleen, lymph nodes, and Peyer's patches (Fig. 1C and D).
Effect of Anti-IgD Suppression on the Immune Responses of Heterozygous Mice.
Heterozygous (BALB X SJL)F1 mice, treated from birth with antibody directed
against a single IgD allotype specificity, were primed with SRBC at 6 wk of age.
They were given a second injection of antigen 5 wk after priming and were assayed
for splenic anti-SRBC IgG PFC of both a and b allotypes 6 d later. The number of
IgG antibody secreting cells of linked allotype specificities was markedly depressed in
these mice (Tables III and IV, protocols 1 and 2) . When the anti-IgD antibody
injections were terminated at the time of the primary antigen injection (protocol 2),
there was little or no recovery in the number of anti-SRBC PFC of the suppressed
allotype produced after boosting (compare protocols 1 and 2) . Weekly injections of
anti-IgD from priming until boosting (protocol 3), or a single injection of anti-IgD
just before priming (protocol 4), caused only a moderate suppression of the PFC
response of the relevant allotype. Unlike the results with mice treated from birth
(protocols 1 and 2), where each animal in the group showed a marked suppression,
the suppression observed with protocols 3 and 4 was variable in that some animals
produced normal PFC responses, whereas others showed a significant depression. It is
interesting to note that in most cases there was a moderate enhancement of the
d % %
Anti-5a (4.22) 7 a 17.9 13.6
42 64.1 48.2
Anti-56 (H6/31 HL) 7 b 16.3 12.6
42 62.8 41 .8
Anti-5a + anti-56 7 a 21.4 82.9
6 30.7 64.6
Percentage of control
Time after Incidence of Serum last anti- Allotype spleen cells concentration delta assayed bearing
of IgG2a of injection IgD of
suppressed suppressed
allotype§ allotype$JACOBSON ET AL.
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Fio. 1 .
￿
Photomicrographs of Peyer's patches in the small intestine of control (A and C) and anti-
IgD-treated (B and D) BALB/c mice . Staining in A and B was with methyl green pyronine, and in
C and D staining was with rabbit anti-IgD followed by goat anti-rabbit Ig and rabbit anti-
peroxidase-peroxidase complexes (PAP technique) .
response of the nonsuppressed allotype . This trend was most consistently seen in
animals treated with anti-5b .
A comparison between IgD-bearing cells of a and b allotypes and the numbers of
anti-SRBC PFC of the linked IgG allotypes revealed some interesting points . Although
there was a significant degree of recovery of IgD-bearing cells of the suppressed
allotype over a 6-wk period after the last injection of anti-IgD (Tables III and IV,
protocol 2), the anti-SRBC PFC response of the linked IgG allotypes was still324
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depressed . In fact, it was as depressed as in mice injected with anti-IgD throughout
the entire immunization period (protocol 1) . The reverse relationship could be seen
with protocol 3 where, although the number of IgD-bearing cells of the suppressed
allotype was low at the time of assay, the secondary PFC response was near normal .
Of particular interest are the observations on heterozygous mice injected simulta-
neously with both anti-Ig-5a and anti-Ig-5b starting at birth (Table V) . These
animals, although they showed a marked depression in the frequency of total IgD-
bearing cells, produced normal or perhaps somewhat enhanced numbers of anti-
SRBC IgG PFC of both linked allotypes .JACOBSON ET AL .
TABLE III
Effect ofAnti-Deltab Treatment on Secondary Immune Responses ofAllotype Heterozygous Mice
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* Days 0, 7, 14, and 21 : 10 hg injected intraperitoneally . Thereafter, 2 ttg/g body weight was injected
weekly, according to the schedule indicated by dots . 4 X 10 8 SRBC were injected intravenously on days
43 and 78, as indicated by arrows. The assay was done on day84 .
$ PFC developed with allotype-specific antisera. 19S PFC subtracted from total . Expressed as geometric
mean x SE.
§ Determined by immunofluorescence . Expressed as arithmetic mean ± SE .
Effect of Anti-Delta' Treatment on SecondaryImmune Responses ofAllotype Heterozygous Mice
Protocol*
* See footnotes to Tables III and IV .
TABLE IV
* Days 0, 7, 14, and 21 : 10 gg was injected intraperitoneally. Thereafter, 2 ttg/g body weight was injected
weekly, according to the schedule indicated by dots . 4 X 10 8 SRBC were injected intravenously, on days
43 and 78, as indicated by arrows . The assaywasdone on day 84 .
$ PFC developed with allotype-specific antisera . 19S PFC subtracted from total . Expressed as geometric
mean x SE .
§ Determined by immunofluorescence . Expressed as arithmetic mean ± SE .
TABLE V
Effect ofSimultaneous Anti-Delta' plus Anti-Deltab Treatment on Secondary Immune
Responses ofAllotype Heterozygous Mice
Anti-SRBC PFC/spleen X
￿
Frequency of spleen cells
Number of
￿
10-3 for allotype
￿
bearing IgDofallotype
mice
1
￿
6
￿
122.9 x 0.65
￿
95 .0 x 0.68
￿
3.1 ± 0.56
￿
4.7 ± 0.80
5
￿
31
￿
79.6x0.34 70.7x0 .41 14.5±0 .71 15.3±0.68
Protocol*
Duration of anti-
I9-5b injections
Num-
ber of
mice
Anti-SRBC PFC per spleen
X 10-3 for allotype$
a b
Frequency ofspleen cells
bearingIgD of allotype§
a b
1
d
0 421 . 77,E
~ . . . . . .. . . . . . . . . . 9 153.7 x 0.62 11 .5 x 1 .20 18 .8 ± 1.20 2.5 ± 0.83
2 ~ . . . . . . . 7 121.3x0.82 8.9x1.20 16.7±1.40 9.6±1.20
3 . . . . . . . . . 10 154.4 x 0.53 45 .8 X 0.56 21 .4 ± 1.10 1.4 ± 0.26
4 9 143.9x0.49 50.3x0.50 21 .4±0.77 6.6±0.71
5 31 79.6x0.34 70.7x0 .41 14.5±0.71 15.3±0.68
Protocol * Duration of anti-
Ig-5a injections
Num-
ber of
mice
Anti-SRBC
X 10-3 for
a
PFC/spleen
allotype$
b
Frequency of spleen cells
bearing IgD of allotype§
a b
1
d
0 421, 771
~ . . . . . . . . . . . . . . . . ~ 12 15.4x 1.14 120.3x0 .61 2.6±0.32 17.4±1.20
2 . .. . .. . .. . 11 26.2x0 .61 132.8x0.46 9.3±1 .50 15.6±1.40
3 . . . . . . . . . .~ 6 52.6x0 .71 49.0x0 .71 2.9±0.65 13.7±1.70
4 - 5 39.3x0 .81 51 .3x0.69 7.0±1 .10 11 .5±0.62
5 31 79.6x0.34 70.7x0 .41 14.5±0 .71 15.3±0.68326
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In two experiments heterozygous mice suppressed with anti-5a, according to
protocols 1 and 2, were injected with TNP-bovine gammaglobulin (BGG) in CFA
instead of SRBC and were boosted with soluble TNP-BGG. As with SRBC, animals
treated according to protocol 2 showed a similar degree of suppression of their anti-
TNP antibody titers of the linked IgG2a allotype (1 :640 vs. 1 :40,000 for controls) as
did mice that had been injected, according to protocol 1, until boosting (mean titer
1 :80). IgG2a antibody titers of the nonsuppressed allotype were comparable in all
groups (1 :40,000).
Additional evaluation of the effect of anti-IgD on serum IgG levels was carried out
at 12 wk of age (Table VI) . When compared with the level of IgD-bearing cells, there
was a concordant decrease in the serum IgG2a concentration of the linked allotype.
Thus, the serum IgG2a allotype levels reflected the numbers of IgD-bearing cells of
that allotype, whereas serum antibody levels reflected the numbers of PFC of that
allotype.
Primary and Secondary Responses to TNP-BA in Homozygous Mice Suppressed with Anti-IgD
from Birth. BALB/c mice injected from birth with anti-Ig-5a received a primary
intravenous injection of TNP-BA at 21 d ofage and a second intravenous injection 10
d later. Some mice were used 4 d after the second antigen injection for analysis of
splenic anti-TNP PFC, whereas other animals were left for assay of serum anti-TNP
titers at 7 d (Table VII) . The anti-IgD treatment had no effect on serum antibody
levels in either the primary or secondary responses or on the number of anti-TNP
PFC in the secondary response, despite the absence of IgD-bearing cells and a marked
depression in total Ig-bearing cells.
Additional groups of suppressed and control BALB/c mice were injected with TNP-
BA in the front footpads and were boosted via the same route 10 d later. PFC in the
brachial lymph nodes were assayed 4 d later (Table VIII). The observed suppression
of the indirect anti-TNP PFC response was statistically significant in one of the two
experiments.
TABLE VI
Concordant Effect of Anti-Delta Treatment on Serum IgG2a Levels
Time
￿
Serum concentration of
* See footnotes to Tables III and IV.
Determined by radioimmune blocking assay. Serum taken on day 84. Ex-
pressed as arithmetic mean ± SE.
Anti-delta injected
Pro-
to-
cot*
after last
anti-
delta in-
jection
d
IgGza immunoglobulin
for allotype$
a b
mg/ml
Num-
her of
mice
1 7 0.3±0.06 1.7±0.18 15
2 42 1 .1±0.15 2 .2±0.26 13
Anti-5a (4.22) 3 7 1 .4 ± 0.15 2.1 ± 0.16 6
4 42 2.0±0.17 1.7±U9 5
1 7 2.2±0.22 0.2±0.08 8
2 42 3.6±0.43 0.7±0.07 7
Anti-5b (H6/31HL)
3 7 2.7±0.75 0.3±0.09 13
4 42 2.5±0.25 0.7±0.13 15
Anti-5a + anti-5b 1 7 1 .9 ± 0.38 1.0 ± 0.11 6
None 5 - 2.3±0.15 1.6±0.09 31JACOBSON ET AL.
TABLE VII
Effect of Treatment with Anti-IgDfrom Birth on Immune Responses ofBALB/c Mice to TNP-BA
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* Intraperitoneal injections of 4.22 anti-5a were given three times a week as follows: 5 hg per injection the
1st 10 d, 10 Wg per injection the next 10 d, and 50 ttg per injection thereafter.
$ 800 Ftg TNP-BA was injected intravenously on days 0 and 10. Sera were examined 7 d after primary or
secondary antigen injection. 7S serum titers were determined in the presence of 0.1 M mercaptoethanol.
Splenic PFC were determined on day 4 after the second injection; 7S PFC were developed with anti-Ig
in the presence of anti-mu in the agar.
§ There were no statistically significant differences between anti-IgD-treated and control mice in any
parameter of the immune response studied. Numbers of mice are in parentheses.
~~ Determined by immunofluorescence .
TABLE VIII
Secondary Immune Response in Lymph Nodes Draining Footpad Injection of TNP-BA ofAnti-IgD-treated
and Normal BALB/c Mice
Experi-
￿
Days of TNP-BA
ment injection*
Geometric Mean X SE (n) of
Anti-IgD
￿
anti-TNP PFC/lymph node
treat-
￿
on day 4
ment$
Frequency ofspleen
cells bearing§
* Dose of TNP-BA in each footpad was 0.8 tlg on day 0 and 0.8 Ftg (experiment 1) or 8 Ftg (experiment 2)
on day 10.
$ Injections of4.22 anti-5a were given three times a week as follows: 5 ttg per injection the 1st 10 d, 10 lsg
per injection the next 10 d, and 50 Ftg per injection thereafter.
§ Determined by immunofluorescence .
~~ P < 0.2.
P < 0.01 .
Response to Other TNP Conjugates by Homozygous Mice Treated with Anti-IgD from
Birth. In vitro experiments have suggested that responses to TNP-BA are much less
dependent on IgD-bearing cells than are responses to thymus-dependent antigens (3) .
In view of the lack of suppression of the splenic PFC response to TNP-BA by mice
chronically suppressed with anti-IgD, the effect of anti-IgD treatment on the in vivo
response to a T dependent antigen (TNP-KLH) was determined (Table IX) . Despite
the usual depression of IgD-bearing cells, there was no significant inhibition of either
Direct Indirect Delta Ig
1 Day 0 and day 10 None 219 i 1.6 1071 X 1.6 (5)11 22.3 ± 5.8 22.1 f 4.6
Day 0 and day 10 Anti-5a 135 X 3.0 223 x 2 .2 (5)11 1 .6 t 0.5 13.8 ± 1.0
Day 10 None 17 x 1 .6 5 X 4.7 (5) ND ND
2 Day 0 and day 10 None 1230 T 2.3 3631 r 1.5 (4)$ 37.1 ± 3.4 ND
Day 0 and day 10 Anti-5a 257 r 1.4 158 T 1 .5 (4)$ 3.8 ± 1.1 ND
Day 10 None 68 1 .2 22 x 1 .8 (4) ND ND
Parameter
Immune
response
studied$
Mice treated with
Anti-Ig5a§ None§
Anti-TNP serum titers (1092 ± SE) Primary 8.5 t 0.3 (10) 8.1 f 0.4 (5)
Secondary 14.3 ± 0.8 (5) 14.7 ± 0.5 (5)
Anti-BA serum titers (loge {' SE) Primary 5.4 ± 0.4 (10) 6.4 ± 0.2 (5)
Secondary 14.7 t 0.2 (5) 14.5 ± 0.2 (5)
7S anti-BA serum titers (loge ± SE) Secondary 11.8 t 0.2 (5) 11 .8 ± 0.9 (5)
19S anti-TNP PFC/spleen (geometric mean )- .SE) Secondary 213,796 X 1.3 (5) 269,153 x 1.4 (12)
7S anti-TNP PFC/spleen (geometric mean T SE) Secondary 478,630 X 1 .3 (5) 891,251 x 1 .5 (12)
Percentage of IgD-bearing cells/spleen ± SE11 0 t 0 (5) 18.4 ± 3.4 (4)
Percentage of Ig-bearing cells/spleen t SE11 6.6 ± 0.6 (5) 22.4 t 4.0 (4)328 PHYSIOLOGY OF IgD
TABLE IX
Primary Responses in Homozygous Mice Treated with Anti-IgDfrom Birth
* Intraperitoneal injections of 4.22 anti-5a (BALB/c) or of H6/3l HL anti-56 (SJL/J) three times a week:
5 pg per injection the 1st 10 d, 10 teg per injection the next 10 d, and 50 ILg per injection thereafter.
$ Indirect plaques were developed by anti-Ig with goat anti-tt added to agar.
§ Determined by immunofluorescence . Expressed as arithmetic mean t SE.
the 19S or 7S responses to TNP-KLH in homozygous mice. If any effect occurred, it
was in the direction of enhancement, especially in the 19S response.
It has been shown that a highly mature B cell subpopulation that is Lyb5 positive
and has a high surface delta:mu ratio is, under normal conditions, responsible for the
response to TNP-Ficoll, a class 2 thymus-independent antigen (25) . The effect of
treating homozygous mice with anti-IgD from birth on their response to TNP-Ficoll
was therefore studied (Table IX). No depression of either the 19S or 7S splenic anti-
TNP PFC responses was observed. The apparent increase in the PFC response of
treated mice was not statistically significant .
Discussion
The results reported here indicate that it is possible to readily suppress the immune
response of one allotype specificity in heterozygous mice by in vivo treatment with
the appropriate anti-IgD antiserum. In contrast, even with fivefold higher doses of
anti-IgD, the immune response of homozygous mice is not suppressed, despite a
virtual absence of IgD-bearing cells and a marked reduction in total Ig-bearing cells.
In agreement with results in homozygous mice, simultaneous treatment of heterozy-
gotes with antisera directed against IgD of both allotypes causes no depression of the
immune response.
In the present studies, recovery from anti-IgD suppression with respect to number
of IgD-bearing cells was slow, particularly in the heterozygous mice, where a normal
ratio of allotypes was not observed even 6 wk after termination of anti-IgD treatment.
Suppressed mice, in some cases, showed a compensatory increase both in the PFC
responses and in the serum IgG28 levels of the alternate allotype. A corresponding
compensatory increase in IgD-bearing cells of the nonsuppressed allotype was not
seen.
Mouse
strain
Antigen on
day 0
Anti-IgD
treatment*
Geom mean r SE (n) ofanti-
TNP PFC/spleen on day 4
19S 7S$
Frequency of spleen cells
bearing§
delta lg
SALB/c TNP-Ficoll None 269,200 25 1 .4 251,200 ) -5 1 .4 (5) 19.0 ± 2.1 24.6 t 3.1
(10 lag)
TNP-Ficoll Anti-Ig-5a 457,100 X 2.0 489,800 X 1 .8 (5) 0.8 ± 0.5 8.2 t 0.7
(10 ,ug)
SALB/c TNP-KLH None 10,200 x 1 .5 7,200 x 1 .2 (6) 17.1 ± 3.4 18.1 f 2.6
(100 ttg)
TNP-KLH Anti-Ig-5a 30,900 x 1 .1 15,500 x 1.3 (3) 0 8.0 ± 0.8
(100 lsg)
SJL/J TNP-KLH None 1,700 X 1 .1 11,000 X 1.1 (3) 28.9 ± 4.6 29.7 ± 4.0
(100 ,ug)
TNP-KLH Anti-Ig-5b 5,200 X 1 .1 5,600 X 1.3 (4) 2.5 ± 1 .4 5.9 ± 1 .6
(100 pg)JACOBSON ET AL.
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The overall results suggest that IgD-bearing cells are not essential for an immune
response in vivo. In homozygous suppressed animals, lacking IgD-bearing cells, the
remaining B cells (^-1/3-1/4 of control) can operate at a normal level. It is therefore
clear that the immune system is able to employ the cell population that is present at
the time of antigen exposure in an effective manner. Thus, it seems that the presence
of IgD on the cell surface is not obligate for the in vivo activation of primary and
secondary immune responses to intravenously injected antigens.
It is known from studies on the rabbit (26) and the chicken (27) that it is far more
difficult to suppress homozygous than heterozygous animals. In homozygous rabbits,
suppression of a VH locus product leads to a compensatory increase in the products of
alternative loci (28). If there were IgD subclasses in the mouse, suppression of
homozygous mice with anti-allotypic antibodies might result in a comparable effect.
This possibility was excluded by the finding that a heterologous anti-IgD also failed
to reveal any IgD-bearing cells in the suppressed mice. Furthermore, studies at the
DNA level have detected only a single IgD locus in the mouse (29) . In heterozygous
animals, in which essentially complete suppression can readily be obtained, a skewed
representation of the allotype tends to persist for a long time after anti-allotype
injection. In the chicken and the rabbit, it was shown that the stability of the altered
allotype expression is due to what has been referred to as B cell clonal dominance (27,
30). In studies on idiotype suppression in mice, clonal dominance has also been
observed (31) . We would suggest that, in line with a network concept of immune
function (32), IgD allotype suppression results in a perturbation of the B cell clone
distribution. A certain distribution of idiotypic specificities occurs and, because of its
stabilizing properties, clonal interactions tend to perpetuate this distribution and
prevent the establishment of new clones. Therefore, the skewed allotype representation
in responses to antigens presented during suppression would tend to persist long after
the suppression wanes. Alternatively, allotype-specific regulatorycellscould determine
and stabilize the prevalence of the alternative allotype in antibody responses of
suppressed heterozygous mice. Thus, in our studies, the effect on the allotype repre-
sentation in the antibody response persists longer than does the suppression of IgD-
bearing cells.
The lack of suppression of the in vivo immune response after chronic treatment
with anti-IgD is not inconsistent with inhibition of in vitro responses. Treatment with
anti-IgD from birth evidently permits an expansion of compensatory cell populations
that probably could not occur under in vitro conditions. It is interesting that the
operation of compensatory mechanisms is seen most dramatically after intravenous
antigen presentation. In the present studies, after footpad injection of antigen, and in
the results of Layton et al. (4), after intraperitoneal injection of antigen, significant
depressions of the 7S secondary immune response were seen in homozygous mice
suppressed with anti-IgD from birth. The variation in results obtained with different
routes of antigen presentation suggests that the capacity for compensation for a lack
of IgD-bearing cells differs in the compartments of the immune system. Presumably,
this reflects differences in the distribution of cell populations in the various compart-
ments. Whether these differences are qualitative or quantitative cannot be determined
from the available data. It seems reasonable to suggest that the patterns of migration
and recirculation of distinctive subsets of cells (e.g., IgD-positive vs. IgD-negative
cells) could account for these differences. One must also take into account the possible330
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influence of antigen concentration and/or epitope density in antibody responses
involving IgD (12, 33) .
The critical conclusion of the present studies is that under some experimental
conditions, an alternative pathway of response, not involving IgD-positive cells, can
be visualized and can operate at a high level of efficiency with respect to primary
responses to TNP-KLH, TNP-BA, and TNP-Ficoll, secondary responses to SRBC and
TNP-BA, and germinal center generation. It should be pointed out that our hypothesis
would lead to different predictions for the results of acute and chronic suppression.
Time would be required for an imbalance of the B cell system to be established as a
consequence of treatment with anti-IgD allotype in heterozygotes. Thus, effects such
as we have been studying would probably only be seen in chronically suppressed
animals. Recently Metcalf et al . (24) have described experiments usinga heterologous
anti-IgD antiserum, the results of which were interpreted along similar lines to those
discussed here. It is interesting that we have found that the capacity to compensate
for the absence of IgD-bearing cells extends even to the response to TNP-Ficoll, which
is normally limited to a subset of B cells that have a high delta:mu ratio of surface Ig
(25) . It should be emphasized that the results reported here in no way contradict the
view that the immune response predominantly proceeds via IgD-bearing cells under
normal conditions.
Summary
The role o£ delta-positive cells in the immune response was studied by comparing
the effects oftreatment with allotype-specific IgD hybridoma antibody on homozygous
BALB/c or SJL/J and heterozygous (BALB X SJL)Fl mice.
Homozygous mice, injected from birth with the relevant anti-delta antibody, made
primary or secondary immune responses to intravenously injected trinitrophenyl
(TNP)-Brucella abortus, TNP-Ficoll, and TNP-keyhole limpet hemocyanin, which did
not differ significantly from those of control mice, despite the fact that IgD+ cells
were depleted and Ig+ cells were markedly reduced in the spleens of treated mice.
Responses in nodes draining a local injection of TNP-Brucella abortus were, however,
significantly suppressed.
Heterozygous mice, injected from birth with either anti-Ig-5a or anti-Ig-5b, showed
a marked reduction in the number of cells producing IgG antibody of linked allotype
specificity in the secondary response to intravenously injected sheep erythrocytes. A
corresponding decrease in the amount of serum IgG2a of that allotype specificity was
also noted. However, in agreement with the results obtained in homozygotes, hetero-
zygotes injected simultaneously with anti-IgD directed against each of the allotypes
made normal, if not enhanced, plaque-forming cells responses of both allotype
specificities. Similarly, serum IgG2a levels were normal in all but one mouse treated in
this fashion.
These results indicate that IgD+ cells are not essential for an immune response in
vivo. Although the delta-positive cell is used preferentially under normal conditions,
it appears that an alternative mechanism exists by which, in the absence ofthese cells,
the animal is able to make a normal immune response.
We would like to thank Dr. Fred Finkelman for his generous gift of rabbit anti-mouse IgD.
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